**Name of journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 26094**

**Manuscript type: Topic Highlights**

**2016 Nonalcoholic Fatty Liver Disease: Global view**

**Genetics of non-alcoholic fatty liver disease: from susceptibility and nutrient interactions to management**

ravi kanth VV *et al*. NAFLD, genetic susceptibility and nutrient interactions

**Vishnubhotla Venkata Ravi Kanth, Mitnala Sasikala, Mithun Sharma, Padaki Nagaraja Rao, Duvvuru Nageshwar Reddy**

**Vishnubhotla Venkata Ravi Kanth, Mitnala Sasikala,** Asian Healthcare Foundation, a research wing of Asian Institute of Gastroenterology, Hyderabad 500082, Telangana, India

**Mithun Sharma, Padaki Nagaraja Rao, Duvvuru Nageshwar Reddy,** Asian Institute of Gastroenterology, Hyderabad 500082, Telangana, India

**Author contributions:** RaviKanth VV wrote the manuscript; Sasikala M Revised the manuscript; Sharma M, Rao PN and Reddy DN Participated in reviewing the manuscript content.

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Dr. Mitnala Sasikala, Head,** Research Labs, Asian Healthcare Foundation, a research wing of Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad 500082, Telangana, India. a[igres.mit@gmail.com](mailto:igres.mit@gmail.com)

**Telephone:** +91-40-23378888-701

**Fax:** +91-40-23324255

**Received:** March 28, 2016

**Peer-review started:** April 1, 2016

**First decision:** April 18, 2016

**Revised:** May 4, 2016

**Accepted:** June 14, 2016

**Article in press:**

**Published online:**

**Abstract**

Genetics plays an important role in determining the susceptibility of an individual to develop a disease. Complex, multi factorial diseases of modern day (diabetes, cardiovascular disease, hypertension and obesity) are a result of disparity between the type of food consumed and genes, suggesting that food which does not match the host genes is probably one of the major reasons for developing life style diseases. Non-alcoholic fatty liver is becoming a global epidemic leading to substantial morbidity. While various genotyping approaches such as whole exome sequencing using Next generation sequencers and Genome wide association studies have identified susceptibility loci for non-alcoholic fatty liver disease (NAFLD) including variants in *PNPLA3* and *TM6SF2* genes apart from others; nutrient based studies emphasized on a combination of Vitamin D, E and omega-3 fatty acids to manage fatty liver disease. However majority of the studies were conducted independent of each other and very few studies explored the interactions between the genetic susceptibility and nutrient interactions. Identifying such interactions will aid in optimizing the nutrition tailor made to an individual’s genetic makeup, thereby aiding in delaying the onset of the disease and its progression. The present topic focuses on studies that identified the genetic susceptibility for NAFLD, nutritional recommendations, and their interactions for better management of NAFLD.

**Key words:** Non-alcoholic fatty liver disease; *PNPLA3* gene; *TM6SF2* gene; genetic susceptibility; nutrient interactions; genotyping

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Various genome wide association and replication studies across ethnicities have consistently associated variants in *PNPLA3* gene with a higher risk of non-alcoholic fatty liver disease (NAFLD). More recently a variant in *TM6SF2* gene was also associated with susceptibility to the disease. Functional studies have established the role of these genes in NAFLD. Gene and nutrient interactions should be the focus of future research in the management of NAFLD.

Ravi Kanth VV, Sasikala M, Sharma M, Rao PN, Reddy DN.Genetics of non-alcoholic fatty liver disease: from susceptibility and nutrient interactions to management. *World J Hepatol* 2016; In press

**INTRODUCTION**

Genetic susceptibility carried by an individual determines the risk of developing a disease. However, not all individuals who carry the risk manifest with the disease, suggesting that, most of the complex multifactorial diseases are the result of interactions between genes and environment. Disease occurrence (onset) or severity may differ in individuals with same genotype exposed to different environmental conditions or vice versa, reiterating the fact that phenotype is the consequence of genotype and environment interactions (Figure 1). Diet, life style, exposure to chemicals and toxins form the major part of environmental risks. Majority of the modern day life style diseases such as diabetes, cardiovascular disease, hypertension, obesity are typically inherited with multifactorial mode of inheritance. It refers to a complex pattern of inheritance where a combination of both genetic and other factors including environmental are involved. Multifactorial conditions do not always manifest despite the fact that the individual carries a genetic variant that increases the risk of disease, putting the emphasis on favorable environment.

Non-alcoholic fatty liver disease (NAFLD) is one of the most important lifestyle based complex and multifactorial diseases. The prevalence of the disease varies markedly in various populations. It ranges between 20%-30% in the Western countries[1], 20%-30% in Europeans[2], 8% in Japanese[3] and 25%-30% in Indians[4]. The spectrum of the disease ranges between steatosis alone on one hand and NASH/cirrhosis/hepatocellular carcinoma on the other. However, the progression through the spectrum involves multiple risks including genetic and environmental interactions, in addition to other risk factors (Obesity, advancing age, diabetes, hypertension, and hypertriglyceridemia). Therefore, understanding genetic susceptibility has been the major focus of recent research in addition to alterations in dietary habits and life style modifications which have been demonstrated to benefit the patients and aid in better management of the disease.

It is imperative for organisms from bacteria to humans to regulate their metabolism vis a vis availability of nutrients for better survival of the species. Nutrient-gene interactions have therefore been an ancient and omnipresent mechanism across species. However research started to explore these interactions only lately and the topic has been of prime importance in the context of disease including NAFLD. This review focuses on the genetic susceptibility identified till date employing various approaches (Exome sequencing, GWAs, candidate gene) thus far and the nutrient risks and the interactions between the two wherever studies are available.

**WHOLE EXOME SEQUENCING AND NAFLD**

Recent advances in sequencing the human genome have transformed methods of identifying genetic susceptibility for complex, multifactorial diseases. With whole exome sequencing studies, it is now possible to sequence protein coding regions of the genome and identify genetic susceptibility for complex diseases in an unbiased manner. Although very few studies are available that exploited this technology, important loci have been identified. A quick search on PUB MED revealed a single whole exome sequencing study in morbidly obese patients of Caucasian origin with NAFLD, that revealed novel damaging mutations in *BBS1* (Bardet-Biedl syndrome 1) gene and MC3R (Melanocortin 3 receptor gene). MC3R gene encodes MC3 a G-protein coupled receptor for melanocyte stimulating hormone and adenocorticitropic hormone. Studies have identified that mice deficient for this gene product have increased fat and play a critical role in weight regulation ("Entrez Gene: MC3R melanocortin 3 receptor"). Further another patient with NAFLD-related cirrhosis was compound heterozygous for rare and damaging mutations in PNPLA3[5]. It is only recently that researchers have started to harness NGS technology to identify genetic susceptibility for complex diseases. In future by exploiting this technology many more important loci may be identified for NAFLD that may aid in better management of the disease.

**GWAS AND NAFLD**

Genome wide association studies (GWAS) are employed to identify genetic susceptibility for complex diseases in an unbiased way. One of the first GWA studies for NAFLD was performed by Romeo et al[6] that used a custom chip of ~9000 non-synonymous variants across the genome. The sample included patients with and without NAFLD of various ethnicities including European, Hispanic and African-American. The liver fat was measured by proton MRS. One variant (rs738409), a G allele encoding I148M in PNPLA3 gene was associated with increased fat level in the liver across all the ethnicities. A list of various GWA studies and the variants identified are given in Table 1. Subsequently various groups have replicated the association of this variant in different ethnicities including Japanese[3,7], Indian[8,9], Chinese[10,11]. Further the variant was also associated with higher levels of ALT, histologic NAFLD including steatosis[7,8].

A meta-analysis of 24 studies that included 9915 patients from different ethnicities, identified that PNPLA3 rs738409 variant was associated with fibrosis severity (OR = 1.32, 95%CI: 1.20-1.45)[12]. Another meta-analysis of 16 studies[13], showed that rs738409 had a strong influence on liver fat accumulation. Individuals with GG homozygous genotype showed 77% higher lipid fat content compared to CC genotype and were susceptible to 3.24 fold aggressive disease and NASH. Further, when the risk associated with heterozygosity was evaluated for the variant, additive genetic model was better at explaining the effect of the variant on the susceptibility to develop NAFLD. However the analysis suggested that carrying two G alleles did not seem to increase the risk of severe histological features. Also, meta-regression showed a negative correlation between male sex and the effect of rs738409 on liver fat content (slope: -2.45 ± 1.04; *P* < 0.02). Importantly, the rs738409 GG genotype versus the CC genotype was associated with a 28% increase in serum alanine aminotransferase levels. Renfan Xu et al[14] recent meta analysis of the rs738409 variant that included 23 case-control studies (6071 NAFLD and 10366 controls) showed a significant association of the variant with NAFLD, NASH. The subgroup and sensitivity analysis revealed that the changes were not influenced by the ethnicities and age of the subjects.

A GWA study conducted[15] in 236 non-Hispanic white woman who were genotyped for 3,24,623 SNPs on the Illumina platform and were assessed for various histologic parameters revealed that NAFLD activity score was associated with rs2645424 in farnesyl diphosphate farnesyl transferase 1 (FDFT1). Further analysis revealed that degree of fibrosis was associated with rs343062, lobular inflammation with rs1227756 in COL13A1), rs6591182, and rs887304 in EFCAB4B. SNPs associated with serum levels of alanine aminotransferase included rs2499604, rs6487679, rs1421201 and rs2710833. However, no significant associations were found between genotypes and steatosis, ballooning degeneration, portal inflammation, or other features of NAFLD.

A meta-analysis[16] carried out across four groups of European ancestry and one of the largest GWA studies for NAFLD was tested for associations with CT measured steatosis initially in the 4 groups independently followed by a meta-analysis. The study involved 7176 individuals that were controlled for age, gender and all the principal components. Variants in or near *PNPLA3, LYPLAL1, PPP1R3B, NCAN/TM6SF2* and *GCKR* genes were found to be associated with hepatic steatosis. These above variants but for *PPP1R3B* were also associated with NASH and fibrosis.

Few GWA studies identified loci associated with the associated parameters of NAFLD and most importantly the liver function tests. Two such studies[17,18] have identified four loci namely SNPs in or near *PNPLA3* (rs2281135, rs738409), *SAMM50* (rs2143571, *CPN1-ERLIN1-CHUK* gene cluster (rs10883437, rs11597390, rs11591741, rs11597086), *TRIB1* (rs2954021) and near *HSD17B13/MAPK10* (rs6834314) that were associated with elevated levels of ALT.

Our pooled genetic study[8], where 19 variants were selected that were associated with NAFLD from 4 GWA studies conducted until 2013 and replicated in patients with and without ultrasound detected NAFLD in Indians. The study identified variants in *PNPLA3, PZP, SAMM50* and *PARVB* were associated with NAFLD. Furthermore, the haplotype data suggested that variants in *PNPLA3, SAMM50* and *PARVB* on chromosome 22 were linked, suggesting that this loci is very important in Indian context. Studies from Japan[3] also associated these loci with NAFLD suggesting that it is an important loci conferring susceptibility in Asian population.

**WHOLE EXOME ASSOCIATION STUDY AND NAFLD**

Two studies published during the same time reported the association of a variant (rs58542926) in *TM6SF2* (transmembrane 6 superfamily member 2) gene with susceptibility to NAFLD[19] and influencing total cholesterol and myocardial infarction risk[20]. The first study identified that the variant in *TM6SF2* gene was associated with hepatic triglyceride content (HTGC) and is a adenine to guanine substitution in coding nucleotide 499, replacing glutamate with lysine at position 167 (c.499A>G; p.Glu167Lys). The frequency of this variant was higher in three ancestries studied (European, African-American and Hispanics). The study suggested that the variant carriers had elevated mean and median HTGC in European and African-American ancestries. The study also identified that there was a reduction in the expression of recombinant protein in cultured hepatocytes by almost 50% by the Glu167Lys *TM6SF2* variant compared to the wild type. Further knockdown of the gene by Adeno-associated virus–mediated short hairpin RNA in mice increased the liver triglyceride content by threefold and decreased very-low-density lipoprotein (VLDL) secretion by half. Based on the above, the study suggested that TM6SF2 activity may be required for normal VLDL secretion and that impaired function of the *TM6SF2* gene causally contributes to NAFLD[19]. Further, the function of the gene was also clearly established, where it is now known to be a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content[21]. The second study[20], systematically assessed coding variants at the genome-wide level to identify novel lipid genes and also evaluate whether low frequency variants with large effect exist, identified a coding variant (p.Glu167Lys) in TM6SF2 gene that modifies total cholesterol levels and further was associated with myocardial infarction.

In an ongoing study at our center, we have replicated these variants (rs58542926 in *TM6SF2* and rs2281135 in *PNPLA3* genes) in 220 patients with NAFLD and 185 controls to date. Both the variants are significantly associated with the disease (*TM6SF2* *p* = 0.00008; *PNPLA3* *p* = 0.002) with a higher risk of the disease (Odds – 2.17, 95%CI: 1.34- 3.52 and 1.85, 95%CI: 1.24-2.76). Further both the variants were significantly associated (*p* > 0.05) with higher ALT and AST levels (Data unpublished).

**CANDIDATE GENE STUDIES (OTHER GENES) AND NAFLD**

Based on the two hit hypothesis as discussed earlier[22], studies have explored genes that have an important role in mechanisms related to lipid metabolism, insulin signaling, oxidative stress, , inflammation and fibrogenesis.

While APCO3 gene is the major gene studied for its role in lipid metabolism (association with higher triglyceride levels), *MTP* gene was studied for its role in regulating synthesis, storage and export of hepatic triglyceride content. A loci on the long arm of chromosome 11 (11q23) harbors genes coding for apolipoproteins, including apolipoprotein *A1 (APOAJ), A4 (APOA4* and *APOC3*[23]. Two polymorphisms T455C (rs2854117) and C482T (rs2854116) in the *APOC3* gene either singly or in combination had 30% higher levels of fasting plasma APOC3 and triglyceride levels as compared to the wild type[24]. Subsequent studies failed to replicate these associations[25,26], including our own study[27]. However we found that the SNPs were associated with higher triglyceride levels. *MTP* gene (microsomal triglyceride transfer protein), located at 4q24[28] is critical for the synthesis and secretion of VLDL (very low density lipoprotein) in the liver. A meta-analysis[29] of most studied polymorphism -493G>T (rs1800591 G>T) in the *MTP* gene suggested that the SNP was significantly associated with higher risk of NAFLD**.**

Genes influencing inflammation and immune responses are known to modify susceptibility to NAFLD. Cytokines not only play an active role in the development of disease, but also in the progression by regulating the inflammatory process[30]. Studies identified a positive correlation between increasing degree of liver fibrosis and levels of TNF-α[31-33] including pediatric NAFLD[34]. Further, polymorphism studies associated a promoter SNP (-238G>A) in *TNF-α* gene with susceptibility to NAFLD in Chinese population[35]. TGF-β (transforming growth factor – beta), known to regulate cell death and lipid metabolism[36], has been shown to be up-regulated and is considered an early event in steatohepatitis that is progressive.

Expression of Interleukin-6 (*IL-6*), a major pro-inflammatory cytokine was shown to be increased in animal models of NAFLD, while in mice, sustained selective up-regulation in the liver resulted in systemic insulin resistance[37]. This was subsequently confirmed in humans[38]. Further, a positive correlation was observed between the expression levels and degree of inflammation and stage of fibrosis. A study identified that -174G/C in the *IL-6* gene was involved in inflammation and insulin resistance and associated with NASH[39], chronic liver disease and Hepatocellular carcinoma[40].

Interleukin-10 (IL-10), an anti-inflammatory cytokine coded by *IL-10* gene[41] has a role in regulating inflammation and its anti-inflammatory properties are well known[42]. T cell, monocyte and macrophage mediated functions are inhibited by IL-10. Different types of the cells in liver including stellate cells, hepatocytes and kupffer cells have shown the presence of IL-10. Few studies that explored the role of the gene, identified the protective role of endogenous role of IL-10 against hepatic steatosis, however they suggested that it does not improve hepatic or whole body insulin sensitivity during high-fat feeding[43]. Furthermore, in an animal model of diet-induced fatty liver disease, inhibition of IL-10 promoted increased expression of inflammatory cytokines, worsened insulin signaling and activated gluconeogenic and lipidogenic pathways[44].

Hepatic insulin resistance is associated with NAFLD and is one of the contributory factors in the pathogenesis of metabolic syndrome. Genetic screening of insulin signaling cascade identified a substitution (Glycine-Arginine) at codon 972 of the *IRS-1* gene (insulin receptor substrate-1) with a prevalence of approximately 9% in Caucasians that was associated with reduced insulin sensitivity. Furthermore, obese individuals heterozygous for this mutation have 50% reduced insulin sensitivity as compared to wild type obese subjects[45]. This variant is known to affect insulin receptor activity predisposing to liver damage and decreased hepatic insulin signaling in patients with NAFLD. It is suggested that insulin signaling might play a causal role in the progression of liver damage in NAFLD[46].

NAFLD pathogenesis is a complex mechanism with involvement of free fatty acid (FFA) oxidation[47,48] and genes encoding proteins that are involved in the oxidation process of FFAs influence the oxidation load in individuals with obesity, insulin resistance and metabolic syndrome[49]. Genes harboring polymorphisms involved in generation and degradation of reactive oxygen species play a crucial role that could be due to excessive oxidation of FFA leading to oxidative stress casing apoptosis and liver injury[50]. Namikawa *et al*[51] reported that the TT genotype in the *MnSOD* gene, the main ROS scavenger in mitochondria, leads to decreased efficiency in the transport of MnSOD to the mitochondria and therefore confers susceptibility for NAFLD. Apart from the *MnSOD* gene, substantial evidence is now available on the role of polymorphisms in genes namely *GSTM1, GSTT1* and *GSTP1*genes that are involved in the generation or degradation of ROS. These genes are known to be involved in the progression to cirrhosis[52].

**NUTRITIONAL RECOMMENDATIONS**

Currently in clinical practice, a combination of Vitamin D, vitamin E and omega-3 fatty acids have shown promise in the treatment of NAFLD and seem to be beneficial in patients with NAFLD. Studies further suggests that apart from nutritional counseling that includes a multidisciplinary team (dietician, psychologist, and physical activity supervisor) aerobic exercises, gradual weight loss, management of NAFLD associated conditions namely diabetes, obesity and metabolic syndrome, nutritional recommendations namely use of 400-800 IU/d vitamin E, 1000 IU/d vitamin D, 1 g/d omega-3 fatty acids, and olive oil containing omega-9 fatty acids seem to benefit in reducing the severity of NAFLD. Also, restricting calorie intake to less than 30 kcal/kg/day and including a balanced diet with low levels of saturated and trans fats and simple sugars, avoiding soft drinks with HFCS (high fructose corn syrup), fast food (trans fats, and reduce red and processed meats), and genetically modified crops seem to be beneficial[53].

**MANAGEMENT OF NAFLD**

Lifestyle modification usually by way of weight reduction through diet and exercises is currently the only proven strategy for managing NAFLD. As obesity is a strong risk and influencing factor for NAFLD, weight loss (≥ 8% of body weight) is effective and is also the first line of therapy. A low caloric diet with reduction in the intake of total fat, saturated fatty acids, trans fatty acids and fructose, increase in physical activity and abstaining from smoking is advantageous and the patients are encouraged to follow these. Antioxidants, anti-inflammatory, insulin sensitizers, lipid lowering agents apart from wide range of drugs and supplements have been evaluated in various studies, both animal and human, however none of these have efficacy on long term use[54,55].

**GENETIC AND NUTRIENT INTERACTIONS**

It is almost imperative that all living organisms either simple or complex multicellular, regulate their metabolism vis a vis nutrient availability. Thus, interactions between nutrition and gene are widespread and an ancient feature across species. However, this aspect has not been explored and it is only recently that research started to uncover the mechanism. In view of the rapid advances made in sequencing human genome enormous amount of genetic data is being generated, particularly with respect to common multigenic, multifactorial conditions including obesity, diabetes, NAFLD *etc*. It is becoming more and more obvious that an individual’s susceptibility to lifestyle disease represents a complex interaction between genetics and environmental interactions. Food and nutrient intake are the important environmental factors and their interactions with genes play a key role in the pathogenesis and progression of polygenic diseases. Therefore, research should be focused on identifying such interactions of genes with nutrients and identifying susceptible genotypes to particular nutrients. This will help us optimize nutrient/diet intake (personalized nutrition) to reduce disease risk[56]. However, there are challenges in analyzing these interactions in the form of genetic heterogeneity and complex nature of human genome, complexity of environmental factors including diet *etc*[57].

NAFLD is considered to be the hepatic manifestation of the metabolic syndrome[58]. The “thrifty genotype” a possible explanation for the steep increase in obesity and diabetes, where periods of famine in the history of modern humans has exerted natural selection in favor of selecting genes favorable for fat storage and this is likely mediated through fertility and not viability selection[59].

Hepatic lipase gene (*HL*) is a lipolytic enzyme that regulates triglyceride levels. Insulin is known to up-regulate the activity of HL through the insulin-responsive elements in the promoter region. It is suggested that higher intake of total and saturated fat is associated with higher activity of *HL* gene. A study reported that this activity is influenced by the -514 C>T polymorphism in the *HL* gene, with significantly stronger associations noted between total dietary fat intake and HL activity in individuals with CT and TT genotypes as compared to the wild type (CC)[60]. Another study[61] that explored epidemiologic genotype-nutrient interactions in obesity, where a total of 42 SNPs in 26 candidate genes were genotyped identified an interaction between -514 C>T in *HL* gene and fiber intake. Further they also suggested that the -681 C>G polymorphism in *PPARG3* gene might interact with the percentage of energy derived from fat in the diet for the development of obesity. However, this was a case-only study with only adult obese women as part of the analysis. A study[62] that examined the interactions between the -514 C>T in *HL* gene, dietary fat and HDL-related measures in 1020 men and 1110 women from the farmingham study reported that individuals with the “TT” genotype may have an impaired adaptation to higher animal fat diets. Furthermore, they suggested that dietary fat intake modifies the effect of the polymorphism in *HL* gene on HDL-C concentrations and subclasses, where the T allele was significantly associated with greater HDL-C concentrations only in subjects consuming <30% of energy from fat and the reverse is true when total fat intake was ≥ 30% of energy.

It is well established that Apolipoprotein A5 gene (*APOA5*) is an important determinant of plasma triglyceride levels. Further it is a component of several lipoprotein fractions including HDL, VLDL[63]. A study[64], investigated the interaction between variants in *APOA5* gene and dietary fat in determining plasma fasting triglycerides, remnant-like particle concentrations and lipoprotein particle size in1001 men and 1147 women from farmingham heart study reported significant gene-diet interactions between the -1131T>C polymorphism in *APOA5* gene and polyunsaturated fatty acid (PUFA) intake were found that determined fasting TGs, RLP concentrations and particle size. However, these interactions were not found for the other polymorphism (56C>G). Further they noted that the -1131C allele was associated with higher fasting TGs and RLP concentrations in only individuals who consumed a high-PUFA diet with > 6% of total energy. The study concluded that individuals who are carriers of -1131C polymorphism in *APOA5* gene and take higher n-6 but not n-3 PUFA, have increased fasting TGs, RLP concentrations, and VLDL size and decreased LDL size, suggesting a more atherogenic lipid profile in these individuals because of the n-6 PUFA-rich diet.

A study[65] that recruited 8 subjects with homozygous genotype for the rs738409G allele in PNPLA3 gene and 10 with C allele, explored the influence of the variant on the ability to lose weight thereby reducing liver fat or change insulin sensitivity. The study identified that the fasting serum insulin and C-peptide concentrations were significantly lower in rs738409G as compared to rs738409C group. Although weight loss was not significantly different between the groups (approximately 3.1 Kg), liver fat decreased by 45% in rs738409G as compared to 18% in the rs738409C group, suggesting weight loss is more effective in decreasing liver fat in rs738409G carriers. Another study[66] that explored the influence of PNPLA3 (rs738409) genotype on hepatic fat and modulation by dietary factors such as PUFAs identified that the ratio of n-6 to n-3 PUFs interacted with the GG genotype to promote hepatic steatosis (Figure 2).

**Future Trends**

In future, testing for variants that pre-dispose to NAFLD along with their nutrient interactions would help identify the type of nutrition to be taken based on individual’s genetic makeup thereby minimizing the risk of fatty infiltration.

**CONCLUSION**

Among all the loci identified thus far, there is a compelling evidence of the association of variants in PNPLA3 with NAFLD and functional role of TM6SF2 in the regulation of liver fat metabolism and hepatic lipid droplet content. It may be prudent to genotype these well characterized variants (PNPLA3) as part of the diagnostic workup for NAFLD, to assess the risk of an individual. Further genotyping in asymptomatic individuals will help in making lifestyle based recommendations, including nutrition to minimize the risk of future disease. As the genetic susceptibility risk cannot be changed, it is important to identify the risk at an early age and manage/lower the other modifiable risks/modifiable triggers to efficiently manage the disease without progressing to subsequent pathologies. Finally, the genetic information along with personalized environment exposures will help in stratifying risk of NAFLD in an individual.

**REFERENCES**

1 **Bellentani S**, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. *Dig Dis* 2010; **28**: 155-161 [PMID: 20460905 DOI: 10.1159/000282080]

2 **Blachier M**, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol* 2013; **58**: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]

3 **Kawaguchi T**, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012; **7**: e38322 [PMID: 22719876 DOI: 10.1371/journal.pone.0038322]

4 **Amarapurkar D**, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. *Ann Hepatol* 2007; **6**: 161-163 [PMID: 17786142]

5 **Gerhard GS**, Chu X, Wood GC, Gerhard GM, Benotti P, Petrick AT, Gabrielsen J, Strodel WE, Still CD, Argyropoulos G. Next-generation sequence analysis of genes associated with obesity and nonalcoholic fatty liver disease-related cirrhosis in extreme obesity. *Hum Hered* 2013; **75**: 144-151 [PMID: 24081230 DOI: 10.1159/000351719]

6 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

7 **Akuta N**, Kawamura Y, Arase Y, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Ikeda K, Kumada H. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan. *Gut Liver* 2016; **10**: 437-445 [PMID: 26610348 DOI: 10.5009/gnl15163]

8 **Kanth VV**, Sasikala M, Rao PN, Steffie Avanthi U, Rao KR, Nageshwar Reddy D. Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: A pilot study. *World J Hepatol* 2014; **6**: 435-442 [PMID: 25018854 DOI: 10.4254/wjh.v6.i6.435]

9 **Bhatt SP**, Nigam P, Misra A, Guleria R, Pandey RM, Pasha MA. Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease. *Metab Syndr Relat Disord* 2013; **11**: 329-335 [PMID: 23734760 DOI: 10.1089/met.2012.0064]

10 **Zhang Y**, Cai W, Song J, Miao L, Zhang B, Xu Q, Zhang L, Yao H. Association between the PNPLA3 I148M polymorphism and non-alcoholic fatty liver disease in the Uygur and Han ethnic groups of northwestern China. *PLoS One* 2014; **9**: e108381 [PMID: 25290313 DOI: 10.1371/journal.pone.0108381]

11 **Peng XE**, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X. Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. *PLoS One* 2012; **7**: e50256 [PMID: 23226254 DOI: 10.1371/journal.pone.0050256]

12 **Singal AG**, Manjunath H, Yopp AC, Beg MS, Marrero JA, Gopal P, Waljee AK. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. *Am J Gastroenterol* 2014; **109**: 325-334 [PMID: 24445574 DOI: 10.1038/ajg.2013.476]

13 **Sookoian S**, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology* 2011; **53**: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]

14 **Xu R**, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. *Sci Rep* 2015; **5**: 9284 [PMID: 25791171 DOI: 10.1038/srep09284]

15 **Chalasani N**, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. *Gastroenterology* 2010; **139**: 1567-176, 1567-176, [PMID: 20708005 DOI: 10.1053/j.gastro.2010.07.057]

16 **Speliotes EK**, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, Shuldiner AR, Butler JL, Tomas M, Hoffmann U, Hwang SJ, Massaro JM, O'Donnell CJ, Sahani DV, Salomaa V, Schadt EE, Schwartz SM, Siscovick DS, Voight BF, Carr JJ, Feitosa MF, Harris TB, Fox CS, Smith AV, Kao WH, Hirschhorn JN, Borecki IB. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. *PLoS Genet* 2011; **7**: e1001324 [PMID: 21423719 DOI: 10.1371/journal.pgen.1001324]

17 **Yuan X**, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, Kooner JS, Mooser V. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. *Am J Hum Genet* 2008; **83**: 520-528 [PMID: 18940312 DOI: 10.1016/j.ajhg.2008.09.012]

18 **Chambers JC**, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, Holm H, Sanna S, Kavousi M, Baumeister SE, Coin LJ, Deng G, Gieger C, Heard-Costa NL, Hottenga JJ, Kühnel B, Kumar V, Lagou V, Liang L, Luan J, Vidal PM, Mateo Leach I, O'Reilly PF, Peden JF, Rahmioglu N, Soininen P, Speliotes EK, Yuan X, Thorleifsson G, Alizadeh BZ, Atwood LD, Borecki IB, Brown MJ, Charoen P, Cucca F, Das D, de Geus EJ, Dixon AL, Döring A, Ehret G, Eyjolfsson GI, Farrall M, Forouhi NG, Friedrich N, Goessling W, Gudbjartsson DF, Harris TB, Hartikainen AL, Heath S, Hirschfield GM, Hofman A, Homuth G, Hyppönen E, Janssen HL, Johnson T, Kangas AJ, Kema IP, Kühn JP, Lai S, Lathrop M, Lerch MM, Li Y, Liang TJ, Lin JP, Loos RJ, Martin NG, Moffatt MF, Montgomery GW, Munroe PB, Musunuru K, Nakamura Y, O'Donnell CJ, Olafsson I, Penninx BW, Pouta A, Prins BP, Prokopenko I, Puls R, Ruokonen A, Savolainen MJ, Schlessinger D, Schouten JN, Seedorf U, Sen-Chowdhry S, Siminovitch KA, Smit JH, Spector TD, Tan W, Teslovich TM, Tukiainen T, Uitterlinden AG, Van der Klauw MM, Vasan RS, Wallace C, Wallaschofski H, Wichmann HE, Willemsen G, Würtz P, Xu C, Yerges-Armstrong LM; Alcohol Genome-wide Association (AlcGen) Consortium; Diabetes Genetics Replication and Meta-analyses (DIAGRAM+) Study; Genetic Investigation of Anthropometric Traits (GIANT) Consortium; Global Lipids Genetics Consortium; Genetics of Liver Disease (GOLD) Consortium; International Consortium for Blood Pressure (ICBP-GWAS); Meta-analyses of Glucose and Insulin-Related Traits Consortium (MAGIC), Abecasis GR, Ahmadi KR, Boomsma DI, Caulfield M, Cookson WO, van Duijn CM, Froguel P, Matsuda K, McCarthy MI, Meisinger C, Mooser V, Pietiläinen KH, Schumann G, Snieder H, Sternberg MJ, Stolk RP, Thomas HC, Thorsteinsdottir U, Uda M, Waeber G, Wareham NJ, Waterworth DM, Watkins H, Whitfield JB, Witteman JC, Wolffenbuttel BH, Fox CS, Ala-Korpela M, Stefansson K, Vollenweider P, Völzke H, Schadt EE, Scott J, Järvelin MR, Elliott P, Kooner JS. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nat Genet.* 2011; **43**: 1131-1138 [PMID: 22001757 doi: 10.1038/ng.970]

19 **Kozlitina J**, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, Vogt TF, Hobbs HH, Cohen JC. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2014; **46**: 352-356 [PMID: 24531328 DOI: 10.1038/ng.2901]

20 **Holmen OL**, Zhang H, Fan Y, Hovelson DH, Schmidt EM, Zhou W, Guo Y, Zhang J, Langhammer A, Løchen ML, Ganesh SK, Vatten L, Skorpen F, Dalen H, Zhang J, Pennathur S, Chen J, Platou C, Mathiesen EB, Wilsgaard T, Njølstad I, Boehnke M, Chen YE, Abecasis GR, Hveem K, Willer CJ. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. *Nat Genet* 2014; **46**: 345-351 [PMID: 24633158 DOI: 10.1038/ng.2926]

21 **Mahdessian H**, Taxiarchis A, Popov S, Silveira A, Franco-Cereceda A, Hamsten A, Eriksson P, van't Hooft F. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. *Proc Natl Acad Sci USA* 2014; **111**: 8913-8918 [PMID: 24927523 DOI: 10.1073/pnas.1323785111]

22 **Day CP**. From fat to inflammation. *Gastroenterology* 2006; **130**: 207-210 [PMID: 16401483 DOI: 10.1053/j.gastro.2005.11.017]

23 **Karathanasis SK**, Oettgen P, Haddad IA, Antonarakis SE. Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4). *Proc Natl Acad Sci USA* 1986; **83**: 8457-8461 [PMID: 3095836]

24 **Petersen KF**, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. *N Engl J Med* 2010; **362**: 1082-1089 [PMID: 20335584 DOI: 10.1056/NEJMoa0907295]

25 **Kozlitina J**, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. *Hepatology* 2011; **53**: 467-474 [PMID: 21274868 DOI: 10.1002/hep.24072]

26 [**TG and HDL Working Group of the Exome Sequencing Project**, National Heart, Lung, and Blood Institute](http://www.ncbi.nlm.nih.gov/pubmed/?term=TG%20and%20HDL%20Working%20Group%20of%20the%20Exome%20Sequencing%20Project%2C%20National%20Heart%2C%20Lung%2C%20and%20Blood%20Institute%5BCorporate%20Author%5D), Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, Masca N, Stirrups K, Kanoni S, Do R, Jun G, Hu Y, Kang HM, Xue C, Goel A, Farrall M, Duga S, Merlini PA, Asselta R, Girelli D, Olivieri O, Martinelli N, Yin W, Reilly D, Speliotes E, Fox CS, Hveem K, Holmen OL, Nikpay M, Farlow DN, Assimes TL, Franceschini N, Robinson J, North KE, Martin LW, DePristo M, Gupta N, Escher SA, Jansson JH, Van Zuydam N, Palmer CN, Wareham N, Koch W, Meitinger T, Peters A, Lieb W, Erbel R, Konig IR, Kruppa J, Degenhardt F, Gottesman O, Bottinger EP, O'Donnell CJ, Psaty BM, Ballantyne CM, Abecasis G, Ordovas JM, Melander O, Watkins H, Orho-Melander M, Ardissino D, Loos RJ, McPherson R, Willer CJ, Erdmann J, Hall AS, Samani NJ, Deloukas P, Schunkert H, Wilson JG, Kooperberg C, Rich SS, Tracy RP, Lin DY, Altshuler D, Gabriel S, Nickerson DA, Jarvik GP, Cupples LA, Reiner AP, Boerwinkle E, Kathiresan S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. *N Engl J Med* 2014; **371**: 22-31 [PMID: 24941081 DOI: 10.1056/NEJMoa1307095]

27 **Ravikanth VV**, Mitnala S, Avanthi US, Manjeera B, Aswini R, Mukherjee RM, Rao PN, Reddy DN. PNPLA3 gene polymorphism but not APOC3 enhances risk for nonalcoholic fatty liver disease in Indian subjects. *J Clin Exp Hepatol* 2013; **3**: S24 [DOI: 10.1016/j.jceh.2013.03.049]

28 **Narcisi TM**, Shoulders CC, Chester SA, Read J, Brett DJ, Harrison GB, Grantham TT, Fox MF, Povey S, de Bruin TW. Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. *Am J Hum Genet* 1995; **57**: 1298-1310 [PMID: 8533758]

29 **Li L**, Wang SJ, Shi K, Chen D, Jia H, Zhu J. Correlation between MTP -493G& gt; T polymorphism and non-alcoholic fatty liver disease risk: a meta-analysis. *Genet Mol Res* 2014; **13**: 10150-10161 [PMID: 25501226 DOI: 10.4238/2014.December.4.9]

30 **Braunersreuther V**, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. *World J Gastroenterol* 2012; **18**: 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727]

31 **Lesmana CR**, Hasan I, Budihusodo U, Gani RA, Krisnuhoni E, Akbar N, Lesmana LA. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. *J Dig Dis* 2009; **10**: 201-206 [PMID: 19659788 DOI: 10.1111/j.1751-2980.2009.00386.x]

32 **Hui JM**, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? *Hepatology* 2004; **40**: 46-54 [PMID: 15239085 DOI: 10.1002/hep.20280]

33 **Crespo J**, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. *Hepatology* 2001; **34**: 1158-1163 [PMID: 11732005 DOI: 10.1053/jhep.2001.29628]

34 **Manco M**, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. *Am J Clin Pathol* 2007; **127**: 954-960 [PMID: 17509993 DOI: 10.1309/6VJ4DWGYDU0XYJ8Q]

35 **Hu ZW**, Luo HB, Xu YM, Guo JW, Deng XL, Tong YW, Tang X. Tumor necrosis factor--alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. *Acta Gastroenterol Belg* 2009; **72**: 215-221 [PMID: 19637776]

36 **Stärkel P**, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP, Horsmans Y. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. *J Hepatol* 2003; **39**: 538-546 [PMID: 12971963 DOI: 10.1016/S0168-8278(03)00360-X]

37 **Nieto-Vazquez I**, Fernández-Veledo S, de Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. *Diabetes* 2008; **57**: 3211-3221 [PMID: 18796617 DOI: 10.2337/db07-1062]

38 **Wieckowska A**, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. *Am J Gastroenterol* 2008; **103**: 1372-1379 [PMID: 18510618 DOI: 10.1111/j.1572-0241.2007.01774.x]

39 **Carulli L**, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, De Palma M, Lonardo A, Ricchi M, Bertolotti M, Carulli N, Loria P. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. *Dig Liver Dis* 2009; **41**: 823-828 [PMID: 19403348 DOI: 10.1016/j.dld.2009.03.005]

40 **Giannitrapani L**, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. *World J Gastroenterol* 2013; **19**: 2449-2455 [PMID: 23674845 DOI: 10.3748/wjg.v19.i16.2449]

41 **Eskdale J**, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. *Immunogenetics* 1997; **46**: 120-128 [PMID: 9162098 DOI: 10.1007/s002510050250]

42 **Couper KN**, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. *J Immunol* 2008; **180**: 5771-5777 [PMID: 18424693 DOI: 10.4049/jimmunol.180.9.5771]

43 **den Boer MA**, Voshol PJ, Schröder-van der Elst JP, Korsheninnikova E, Ouwens DM, Kuipers F, Havekes LM, Romijn JA. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. *Endocrinology* 2006; **147**: 4553-4558 [PMID: 16709607 DOI: 10.1210/en.2006-0417]

44 **Cintra DE**, Pauli JR, Araújo EP, Moraes JC, de Souza CT, Milanski M, Morari J, Gambero A, Saad MJ, Velloso LA. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. *J Hepatol* 2008; **48**: 628-637 [PMID: 18267346 DOI: 10.1016/j.jhep.2007.12.017]

45 **Pedersen O**. Genetics of insulin resistance. *Exp Clin Endocrinol Diabetes* 1999; **107**: 113-118 [PMID: 10320051 DOI: 10.1055/s-0029-1212085]

46 **Dongiovanni P**, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, Leathart JB, Pietrobattista A, Burt AD, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Marchesini G, Day CP, Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. *Gut* 2010; **59**: 267-273 [PMID: 20176643 DOI: 10.1136/gut.2009.190801]

47 **Sanyal AJ**, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology* 2001; **120**: 1183-1192 [PMID: 11266382 DOI: 10.1053/gast.2001.23256]

48 **Day CP**. Pathogenesis of steatohepatitis. *Best Pract Res Clin Gastroenterol* 2002; **16**: 663-678 [PMID: 12406438 DOI: 10.1053/bega.2002.0333]

49 **Day CP**. From fat to inflammation. *Gastroenterology* 2006; **130**: 207-210 [PMID: 16401483 DOI: 10.1053/j.gastro.2005.11.017]

50 **Wang K**. Molecular mechanisms of hepatic apoptosis. *Cell Death Dis* 2014; 5: e996 [PMID: 24434519 doi: 10.1038/cddis.2013.499]

51 **Namikawa C**, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, Onishi S. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. *J Hepatol* 2004; **40**: 781-786 [PMID: 15094225 DOI: 10.1016/j.jhep.2004.01.028]

52 **Ghobadloo SM**, Yaghmaei B, Bakayev V, Goudarzi H, Noorinayer B, Rad FH, Samiy S, Aghabozorghi S, Zali MR. GSTP1, GSTM1, and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis. *J Gastrointest Surg* 2004; **8**: 423-427 [PMID: 15120366 DOI: 10.1016/j.gassur.2004.02.005]

53 **Assy N**. Nutritional recommendations for patients with non-alcoholic fatty liver diseases. *World J Gastroenterol* 2011; **17**: 3375-3376 [PMID: 21876629 DOI: 10.3748/wjg.v17.i29.3375]

54 **Eslamparast T**, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. *World J Hepatol* 2015; **7**: 204-212 [PMID: 25729475 DOI: 10.4254/wjh.v7.i2.204]

55 **Dongiovanni P**, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. *J Nutr Biochem* 2016; **29**: 1-11 [PMID: 26895659 DOI: 10.1016/j.jnutbio.2015.08.024]

56 **Phillips CM**, Tierney AC, Roche HM. Gene-nutrient interactions in the metabolic syndrome. *J Nutrigenet Nutrigenomics* 2008; **1**: 136-151 [PMID: 19776623 DOI: 10.1159/000112461]

57 **Wise C**, Kaput J. A strategy for analyzing gene-nutrient interactions in type 2 diabetes. *J Diabetes Sci Technol* 2009; **3**: 710-721 [PMID: 20144318 DOI: 10.1177/193229680900300416]

58 **Kim CH**, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. *Cleve Clin J Med* 2008; **75**: 721-728 [PMID: 18939388 DOI: 10.3949/ccjm.75.10.721]

59 **Prentice AM**, Hennig BJ, Fulford AJ. Evolutionary origins of the obesity epidemic: natural selection of thrifty genes or genetic drift following predation release? *Int J Obes (Lond)* 2008; **32**: 1607-1610 [PMID: 18852700 DOI: 10.1038/ijo.2008.147]

60 **Bos G**, Snijder MB, Nijpels G, Dekker JM, Stehouwer CD, Bouter LM, Heine RJ, Jansen H. Opposite contributions of trunk and leg fat mass with plasma lipase activities: the Hoorn study. *Obes Res* 2005; **13**: 1817-1823 [PMID: 16286530 DOI: 10.1038/oby.2005.221]

61 **Santos JL**, Boutin P, Verdich C, Holst C, Larsen LH, Toubro S, Dina C, Saris WH, Blaak EE, Hoffstedt J, Taylor MA, Polak J, Clement K, Langin D, Astrup A, Froguel P, Pedersen O, Sorensen TI, Martinez JA. Genotype-by-nutrient interactions assessed in European obese women. A case-only study. *Eur J Nutr* 2006; **45**: 454-462 [PMID: 17080261 DOI: 10.1007/s00394-006-0619-6]

62 **Ordovas JM**, Corella D, Demissie S, Cupples LA, Couture P, Coltell O, Wilson PW, Schaefer EJ, Tucker KL. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham Study. *Circulation* 2002; **106**: 2315-2321 [PMID: 12403660 DOI: 10.1161/01.CIR.0000036597.52291.C9]

63 **Nilsson SK**, Christensen S, Raarup MK, Ryan RO, Nielsen MS, Olivecrona G. "Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families". *The Journal of Biological Chemistry* 2008; **283**: 25920–25927 [PMID: 18603531 doi: 10.1074/jbc.M802721200]

64 **Lai CQ**, Corella D, Demissie S, Cupples LA, Adiconis X, Zhu Y, Parnell LD, Tucker KL, Ordovas JM. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study. *Circulation* 2006; **113**: 2062-2070 [PMID: 16636175 DOI: 10.1161/CIRCULATIONAHA.105.577296]

65 **Sevastianova K**, Kotronen A, Gastaldelli A, Perttilä J, Hakkarainen A, Lundbom J, Suojanen L, Orho-Melander M, Lundbom N, Ferrannini E, Rissanen A, Olkkonen VM, Yki-Järvinen H. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. *Am J Clin Nutr* 2011; **94**: 104-111 [PMID: 21525193 DOI: 10.3945/ajcn.111.012369]

66 **Santoro N**, Savoye M, Kim G, Marotto K, Shaw MM, Pierpont B, Caprio S. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. *PLoS One* 2012; **7**: e37827 [PMID: 22629460 DOI: 10.1371/journal.pone.0037827]

67 **Kitamoto T**, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A, Hotta K. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. *Hum Genet* 2013; **132**: 783-792 [PMID: 23535911 DOI: 10.1007/s00439-013-1294-3]

**P-Reviewer:** Ampuero J, Higuera-de la Tijera MF, Joven J

**S-Editor:** Gong ZM **L-Editor:** **E-Editor:**

Favorable environment

No or delayed disease onset

Risk environment

Early disease onset or faster progression

Genetically susceptible

Genetically susceptible

Genetically susceptible

Genetically susceptible

Genetically susceptible

Genetically susceptible

**Figure 1 Genetic and environmental interactions to produce a phenotype.**

PNPLA3

rs738409

(GG genotype)

1. **Higher n-3 Vs n-6 PUFAs intake**
2. **Weight loss**
3. **Abstaining from alcohol**

**Better Disease management**

1. **Higher n-6 PUFA intake**
2. **Alcohol consumption**

**Higher risk of NAFLD**

**PNPLA3-148M**

**↓ TG Hydrolysis**

**↑ Lipogenic Activity**

**Steatosis ALT/AST**

**Figure 2 Genotype (rs738409) in *PNPLA3* gene and its interactions.**

**Table 1 List of genome/exome wide association studies and loci identified for non-alcoholic fatty liver disease**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Authors** | **Phenotype associated with** | **Ancestry of samples included** | **Genotyping platform** | **Discovery sample size** | **Replication sample size** | **Genes** |
| Romeo *et al*[6], 2008 | Increased hepatic fat levels and inflammation | Hispanic, African American and European American individuals. | Perlegen Sciences Custom array (12138 NS variation) | 2111 individuals with MRS measured hepatic steatosis | None | *PNPLA3* |
| Chalasani  *et al*[15], 2010 | Features of hepatic histology | Non-Hispanic white women | Illumina (324,623 SNPs) | 236, non-Hispanic white women | None | *FDFT1, rs343062 (Chr 7), COL13A1, rs6591182 (Chr 11), EFCAB4B, rs2499604 (chr 1), PZP, rs1421201 (Chr 18) rs2710833 (Chr 4)* |
| Speliotes  *et al*[16], 2011 | CT measured hepatic steatosis | European american including Amish | Affymetrix, Illumina | 7126 with CT measured hepatic steatosis | 592/1405 | *PNPLA3, NCAN, PPP1R3B, GCKR, LYPLAL1* |
| Kawaguchi  *et al*[3], 2012 | NAFLD | Japanese | Illumina | 529 patients consisting of four NAFLD subgroups (Matteoni’s classification) | None | *PNPLA3, SAMM50, PARVB, HS3ST1-HSP90AB2P, YIPF1* |
| Kitamoto  *et al*[67], 2013 | NAFLD | Japanese | Illumina | 392 NAFLD and 934 controls | 172 NAFLD and 1012 controls | *PNPLA3, SAMM50, PARVB gene* |
| Kozlitina  *et al*[19], 2014 | MRS measured hepatic steatosis | Hispanic. African American and European | Illumina | 2,736 | None | *PNPLA3 and TM6SF2* |

NAFLD: non-alcoholic fatty liver disease; CT: Computed tomography.

**Table 2 Functional role of major genes associated with non-alcoholic fatty liver disease identified by genome/exome wide association studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Protein** | **Cellular location1** | **Function1** | **Chromosome location2** | **Number of exons and size2** | **Pathway/biologic function1** | **Tissues expressed1** |
| *PNPLA3* | Patatin-like phospholipase domain-containing protein 3 | Lipid droplets | Triacyl glycerol lipase and acylglycerol O-cyltransferase activities | Chromosome 22: 43,923,739-43,964,488 (forward strand) | 9 (2805 bp) | Triacyl glycerol degradation and in glycerol-lipid metabolism | Liver, gall bladder, kidney, exocrine pancreas, seminal vesicles, intestine and salivary glands |
| *TM6SF2* | Transmembrane 6 superfamily member 2 | Endoplasmic reticulum (ER) and the ER-golgi intermediate compartment | Regulation of fat in liver influencing triglyceride secretion and lipid droplet content | Chromosome 19: 19,264,364-19,273,391 (reverse strand) | 10 (1505 bp) | Promotes very low density lipoprotein export | Liver and intestine |
| *SAMM50* | Sorting And Assembly Machinery Component 50 Homolog | Outer mitochondrial membrane | Assembly of beta-barrel proteins | Chromosome 22: 43,955,421-44,010,531 (Forward strand) | 15 (1717) | Transport to the Golgi and subsequent modification and Mitochondrial protein import. | Liver, Muscle, skeletal, lung adipocyte, colon and other tissues |
| *PARVB* | Parvin, Beta | Cytoplasm | Involved in the reorganization of the actin cytoskeleton and formation of lamellipodia. | Chromosome 22: 44,024,277-44,172,949 (Forward strand) | 13 (5429 bp) | ERK signaling and Focal adhesion | Liver, Muscle, skeletal, lung adipocyte, colon and other tissues |
| *NCAN* | Neurocan | Extracellular, Golgi lumen | Modulates neuronal adhesion and neurite growth during development | Chromosome 19: 19,211,973-19,252,233 (forward strand) | 15 (6387 bp) | Developmental | Liver, Muscle, skeletal, lung adipocyte, colon and other tissues |
| *PPP1R3B,* | Protein Phosphatase 1, Regulatory Subunit 3B | Glycogen granule | Acts as glycogen targeting subunit for phosphatase PP1 | Chromosome 8: 9,136,255-9,151,574 (reverse strand) | 2 (5548 bp) | Regulating glycogen synthesis | Liver, skeletal muscle |
| *GCKR* | Glucokinase (Hexokinase 4) Regulator | Cytoplasm, nucleus | Inhibits glucokinase by forming an inactive complex with this enzyme. The affinity of GCKR for GK is modulated by fructose metabolites | Chromosome 2: 27,496,842-27,523,684 (forward strand) | 19 (2186 bp) | Carbohydrate metabolism | Liver, Pancreas, colon and other tissues |
| *LYPLAL1* | Lysophospholipase-Like 1 | Cytoplasm | Depalmitoylating activity. | Chromosome 1: 219,173,844-219,212,865 (forward strand) | 5 (1898bp) | Negative regulation of golgi to plasma membrane protein transport | Liver, Muscle, skeletal, lung adipocyte, colon and other tissues |

1Data extracted from <http://www.genecards.org/>; 2data extracted from ENSEBL http://asia.ensembl.org/index.html.